PRO-FAST: Physiological and Sensory Responses to Prolonged Fasting in Humans

Sponsor
University of Bath (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05977569
Collaborator
University of Nottingham (Other)
7
1
1
35.1
0.2

Study Details

Study Description

Brief Summary

This study aims to establish the metabolic/molecular response in both adipose tissue and skeletal muscle as well as sensory experiences (pain, fatigue, drive) to prolonged fasting of 3 days duration. Participants will undergo sequential meal assessment before and after a 3 day fast with measures taken throughout each fasting day.

Condition or Disease Intervention/Treatment Phase
  • Other: Prolonged Fasting
N/A

Detailed Description

This study will employ a single-arm, non-randomised design in which participants will act as their own control prior to undergoing 3 days of fasting. The control phase includes 3 days of habitual energy balance assessment before coming into the laboratory for baseline meal testing with blood, muscle, and adipose samples as well as anthropometric assessment.

Participants will then be provided with a standardised lunch to be consumed around midday and a standardised dinner to be consumed at 2000 h.

Participants will then be asked to refrain from caloric intake for 3 days until they return to the laboratory for follow up measures.

Participants will be provided with monitoring equipment throughout the 3 days of fasting and will be asked to provide a blood sample at 0800 h each day alongside self recording of blood pressure, weight, and urinary ketones each day. On the middle day (day 2) participants will also be asked to come into the lab to provide a blood sample at 2000 h.

The follow up visit will be identical to that performed before the fast, including meal testing, blood, muscle, and adipose samples.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
7 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Physiological and Sensory Responses to Prolonged Fasting in Humans
Actual Study Start Date :
Jun 28, 2021
Anticipated Primary Completion Date :
May 30, 2024
Anticipated Study Completion Date :
May 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Prolonged Fasting

All participants are asked to act as their own control prior to being asked to undergo 3 days of fasting.

Other: Prolonged Fasting
Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.

Outcome Measures

Primary Outcome Measures

  1. Change in postprandial insulin responses [3 days]

    Change in postprandial insulin (mmol/L) response to a standardised meal before and after 3 days of fasting.

Secondary Outcome Measures

  1. Change in circulating glycerol and non-esterified fatty acids [1 day, 2 days, 3 days]

    Change in indices of lipolysis from adipose tissue in response to prolonged fasting (Glycerol mmol/L; NEFA mmol/L)

  2. Change in Autophagy [3 days]

    Change in autophagic flux in response to prolonged fasting, assessed in skeletal muscle and circulating neutrophils.

  3. Change in plasma lactate [1 day, 2 days, 3 days]

    Change in plasma lactate in response to prolonged fasting (indices of Cori cycle)

  4. Change in plasma pyruvate [1 day, 2 days, 3 days]

    Change in plasma pyruvate in response to prolonged fasting (indices of Cori cycle)

  5. Change in ketosis. [1 day, 2 days, 3 days.]

    Change in urinary (acetoacetate) ketones in response to prolonged fasting.

  6. Change in ketosis. [1 day, 2 days, 3 days.]

    Change in circulating (beta-hydroxybutyrate) ketones in response to prolonged fasting.

  7. Change in body mass [1 day, 2 days, 3 days.]

    Change in body mass, pre-post, and during the prolonged fast.

  8. Change in blood pressure [1 day, 2 days, 3 days.]

    Change in blood pressure pre-, post-, and during the prolonged fast

  9. Change in interstitial fluid glucose concentrations [1 day, 2 days, 3 days.]

    Change in interstitial fluid glucose concentrations pre-, post-, and during the prolonged fast (assessed via continual glucose monitoring)

  10. Change in amino acid metabolism [3 days.]

    Change in amino acid metabolism (i.e. BCAAs and ketoacids) in skeletal muscle

  11. Change in amino acid metabolism [3 days.]

    Change in amino acid metabolism (i.e. BCAAs and ketoacids) in adipose tissue

  12. Change in amino acid metabolism [3 days.]

    Change in amino acid metabolism (i.e. BCAAs and ketoacids) in circulation

  13. Change in postprandial glucose responses. [3 days.]

    Change in postprandial glucose (mmol/L) response to a standardised meal before and after 3 days of fasting.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • • Body mass index 20.0-29.9 kg∙m-2

  • Age 18-45 years

  • Willing to abstain from food intake for just over 3 days (~82 hours)

  • Able and willing to provide informed consent and safely comply with study procedures

  • Females to maintain record of regular menstrual cycle phase or contraceptive use

  • No anticipated changes in lifestyle during the study (e.g. holidays or exercise programmes)

Exclusion Criteria:
  • • Any reported condition or behaviour deemed either to pose undue personal risk to the participant or introduce bias

  • Any diagnosed metabolic disease (e.g. type 1 or type 2 diabetes)

  • Any reported use of substances which may pose undue personal risk to the participants or introduce bias into the experiment

  • Pregnancy

  • Breastfeeding

  • Lifestyle not conforming to standard sleep-wake cycle (e.g. shift worker)

  • History of eating disorders (e.g. anorexia)

  • Any reported recent (<6 months) change in body mass (± 3%)

  • Uncontrolled hyperthyroidism

  • Advanced cerebrovascular insufficiency or dementia

  • Advanced liver or kidney insufficiency

  • History of migraine and or headache

  • Psychotic disorders

  • Unstable or severe coronary artery disease

  • Retinal detachment

  • Duodenal or stomach ulcer

  • Cancer and malignant disease

  • Regular use of Non-steroidal anti-inflammatory drugs (NSAIDs)

  • Use of Systemic corticoids

  • Use of Antihypertensives (especially beta-blockers and diuretics)

  • Use of Antidiabetics

  • Use of Anti-coagulants

  • Use of Psychotropics (especially neuroleptics and lithium)

  • Use of Anticonvulsants.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Bath Bath Somerset United Kingdom BA2 7AY

Sponsors and Collaborators

  • University of Bath
  • University of Nottingham

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
James Betts, Professor, University of Bath
ClinicalTrials.gov Identifier:
NCT05977569
Other Study ID Numbers:
  • PF
First Posted:
Aug 4, 2023
Last Update Posted:
Aug 4, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 4, 2023